Cargando…

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

BACKGROUND: The introduction of adjuvant systemic treatment has significantly improved recurrence-free survival in patients with resectable high-risk melanoma. Adjuvant treatment with immune checkpoint inhibitors and targeted therapy, however, substantially impacts health care budgets, while the num...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulder, E.E.A.P., Smit, L., Grünhagen, D.J., Verhoef, C., Sleijfer, S., van der Veldt, A.A.M., Uyl-de Groot, C.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599106/ https://www.ncbi.nlm.nih.gov/pubmed/34781194 http://dx.doi.org/10.1016/j.esmoop.2021.100303

Ejemplares similares

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma
por: Derks, S.H.A.E., et al.
Publicado: (2022)

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma
por: Mulder, E.E.A.P., et al.
Publicado: (2020)

Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study
por: Verver, D, et al.
Publicado: (2019)

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
por: Franken, M.G., et al.
Publicado: (2021)

Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007–2017
por: NOELS, Eline, et al.
Publicado: (2020)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study
por: Zhou, Catherine, et al.
Publicado: (2021)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
por: Mulder, Evalyn E.A.P., et al.
Publicado: (2022)

Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
por: Timbergen, Milea J. M., et al.
Publicado: (2019)

Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2022)

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
por: de Groot, S., et al.
Publicado: (2017)

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
por: De Groot, S., et al.
Publicado: (2016)

Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells
por: Kraan, J, et al.
Publicado: (2014)

The cost of aging: Economic growth perspectives for Europe
por: Jayawardhana, Thaveesha, et al.
Publicado: (2023)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases
por: Meyer, Y. M., et al.
Publicado: (2022)

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision
por: van de Voort, Elles MF, et al.
Publicado: (2022)

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma
por: Kamminga, Nadia C.W., et al.
Publicado: (2022)

Socio-economic burden of cystic fibrosis in Europe: a systematic review of cost of illness evidence
por: D'Ambrosio, F, et al.
Publicado: (2023)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Development and validation of a nomogram to predict recurrence and melanoma‐specific mortality in patients with negative sentinel lymph nodes
por: Verver, D., et al.
Publicado: (2018)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Cost Containment in Europe
por: Culyer, A. J.
Publicado: (1989)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
por: Verver, Danielle, et al.
Publicado: (2021)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

Acute and cumulative effects of carboplatin on renal function.
por: Sleijfer, D. T., et al.
Publicado: (1989)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gafm3no06f4432mqgflfjcm47j